RPL36AP45

Across TCGA pan-cancer cohorts, RPL36AP45 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated RPL36AP45 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RPL36AP45 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL36AP45 expression acts as an unfavorable survival marker, although some lineages such as CESC and UVM show a favorable association.

LIHC, CESC, and UVM are the cancer types where RPL36AP45 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Quartile	All	0.308	0.506	.002	78	view →
CESC	OS	Tertile	II,III,IV	0.924	0.725	.005	62	view →
UVM	DFS	Median	II,III,IV	0.741	0.430	.001	50	view →
READ	OS	Median	All	0.840	0.976	<.001	43	view →
COAD	OS	Quartile	III,IV	0.879	0.388	.006	33	view →
SKCM	DFS	Median	All	0.330	0.155	.001	29	view →
ACC	DFS	Median	All	0.528	0.787	.002	28	view →
BLCA	OS	Tertile	III,IV	0.552	0.160	.011	21	view →
LAML	DFS	Quartile	All	0.335	0.786	<.001	20	view →
BRCA	OS	Tertile	III,IV	0.744	0.347	.010	15	view →
HNSC	DFS	Tertile	II,III,IV	0.533	0.728	.013	14	view →
STAD	DFS	Median	II,III,IV	0.480	0.585	.021	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

RPL36AP45–LIHC (DFS)

Open the LIHC breakdown →